Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC.RYTM · Entity 3693 | Chief Medical Officer | February 14, 2018 | February 16, 2018 |
| Verve Therapeutics, Inc.VERV · Entity 11259 | Chief Medical Officer | February 14, 2024 | February 16, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
RHYTHM PHARMACEUTICALS, INC.
Report date February 14, 2018 · Filed February 16, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.79 · Expires 2028-02-13 | Direct | 25,000 |
Reported balance
After 2018-02-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-02-14 · Grant · Acquired 25,000 · Balance 25,000 F1: This option was granted on February 14, 2018 and the shares underlying this option vest in sixteen equal quarterly installments. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.79 · Expires 2028-02-13 | Direct | 25,000 |
Reported balance
After 2018-02-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-02-14 · Grant · Acquired 25,000 · Balance 25,000 F2: This option was granted on February 14, 2018 and the shares underlying this option shall vest upon completion of a milestone. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on February 14, 2018 and the shares underlying this option vest in sixteen equal quarterly installments.
F2: This option was granted on February 14, 2018 and the shares underlying this option shall vest upon completion of a milestone.
Verve Therapeutics, Inc.
Report date February 14, 2024 · Filed February 16, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.75 · Expires 2034-02-13 | Direct | 90,000 |
Reported balance
After 2024-02-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-02-14 · Grant · Acquired 90,000 · Balance 90,000 F1: The option was granted on February 14, 2024. 25% of the shares underlying the option will vest on February 14, 2025, and the remainder are scheduled to vest in equal monthly installments thereafter until February 14, 2028. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 22,000 |
Reported balance
After 2024-02-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-02-14 · Grant · Acquired 22,000 · Balance 22,000 F2: Each restricted stock unit represents a contingent right to receive one share of common stock. F3: On February 14, 2024, the reporting person was granted restricted stock units, vesting in four equal annual installments, beginning on April 1, 2025, and the remaining three installments vesting on April 1, 2026, April 1, 2027 and April 1, 2028. |
Filing footnotes · ownership attribution and instrument terms
F1: The option was granted on February 14, 2024. 25% of the shares underlying the option will vest on February 14, 2025, and the remainder are scheduled to vest in equal monthly installments thereafter until February 14, 2028.
F2: Each restricted stock unit represents a contingent right to receive one share of common stock.
F3: On February 14, 2024, the reporting person was granted restricted stock units, vesting in four equal annual installments, beginning on April 1, 2025, and the remaining three installments vesting on April 1, 2026, April 1, 2027 and April 1, 2028.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 14, 2024 Filed Feb 16, 2024 16:30 UTC | Verve Therapeutics, Inc. VERV · Entity 11259 | GrantRestricted Stock Units · Derivative | 22,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-016428 · ownership.xml · derivative · entry 2 Fiedorek Fred T. · CIK 0001657185 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F3 · derivative.exercise_date: On February 14, 2024, the reporting person was granted restricted stock units, vesting in four equal annual installments, beginning on April 1, 2025, and the remaining three installments vesting on April 1, 2026, April 1, 2027 and April 1, 2028. F3 · derivative.expiration_date: On February 14, 2024, the reporting person was granted restricted stock units, vesting in four equal annual installments, beginning on April 1, 2025, and the remaining three installments vesting on April 1, 2026, April 1, 2027 and April 1, 2028. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 16:30 UTC | Verve Therapeutics, Inc. VERV · Entity 11259 | GrantStock Option (right to buy) · Derivative | 90,000 | $0.00 Strike: $12.75 | $0.00 |
DisclosureSEC source: 0000950170-24-016428 · ownership.xml · derivative · entry 1 Fiedorek Fred T. · CIK 0001657185 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2034-02-13 F1 · derivative.exercise_date: The option was granted on February 14, 2024. 25% of the shares underlying the option will vest on February 14, 2025, and the remainder are scheduled to vest in equal monthly installments thereafter until February 14, 2028. Read SEC document |
| September 18, 2023 Filed Sep 19, 2023 17:05 UTC | Verve Therapeutics, Inc. VERV · Entity 11259 | GrantStock Option (right to buy) · Derivative | 180,000 | $0.00 Strike: $12.71 | $0.00 |
DisclosureSEC source: 0001209191-23-049999 · doc4.xml · derivative · entry 1 Fiedorek Fred T. · CIK 0001657185 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,000 Underlying: Common Stock · 180,000 shares Expires 2033-09-17 F1 · derivative.exercise_date: The option was granted on September 18, 2023. 25% of the shares underlying the option will vest on September 18, 2024, and the remainder are scheduled to vest in equal monthly installments thereafter until September 18, 2027. Read SEC document |
| February 14, 2018 Filed Feb 16, 2018 21:03 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantEmployee Stock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $25.79 | $0.00 |
DisclosureSEC source: 0001104659-18-010368 · a4.xml · derivative · entry 2 Fiedorek Fred T. · CIK 0001657185 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-02-13 F2 · derivative.exercise_date: This option was granted on February 14, 2018 and the shares underlying this option shall vest upon completion of a milestone. Read SEC document |
| February 14, 2018 Filed Feb 16, 2018 21:03 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantEmployee Stock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $25.79 | $0.00 |
DisclosureSEC source: 0001104659-18-010368 · a4.xml · derivative · entry 1 Fiedorek Fred T. · CIK 0001657185 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-02-13 F1 · derivative.exercise_date: This option was granted on February 14, 2018 and the shares underlying this option vest in sixteen equal quarterly installments. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.